A South San Francisco startup led by veterans of biotech stalwart Genentech Inc. and its parent company Roche wants to raise $86.25 million in an initial public offering.
RAPT Therapeutics Inc. — known until May as FLX Bio Inc. — expects to use the IPO booty to fund development of cancer-fighting FLX-475 through results of an ongoing Phase I/II clinical trial, fund an early-stage safety trial of RPT-193 in the itchy skin condition known as atopic dermatitis and develop other drug candidates,…
